Page 11 - Read Online

effective than any late intervention. Several diagnostic strategies Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T. Risk
lie in the future with the potential identification of circulating factors for hepatocellular carcinoma among patients with chronic liver
disease. N Engl J Med 1993;328:1797-801.
tumor cells or identification of a premalignant signature like 16. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing
epigenetic changes. Despite our best efforts to diagnose HCC increase in the incidence of hepatocellular carcinoma in the United
in earlier stages, this will not be feasible in most. Therapeutic States: an update. Ann Intern Med 2003;139:817-23.
efforts should be redoubled into the development of new drug 17. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, Chen DS. Role
delivery systems and platforms to improve chemotherapeutic of hepatitis B virus precore/core promoter mutations and serum viral
load on noncirrhotic hepatocellular carcinoma: a case-control study.
monotherapy or platform assisted surgery with agents such as J Infect Dis 2006;194:594-9.
nanoparticle and liposomal delivery systems. 18. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN,
You SL, Chen DS, Liaw YF, Chen CJ; REVEAL-HBV Study Group.
Associations between hepatitis B virus genotype and mutants and the
REFERENCES risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-43.
19. Iannacone M, Sitia G, Ruggeri ZM, Guidotti LG. HBV pathogenesis
1. Surveillance Research Program, National Cancer Institute Fast in animal models: recent advances on the role of platelets. J Hepatol
Stats: an interactive tool for access to SEER cancer statistics; 2007;46:719-26.
November 10, 2011. Available from: http://www.seer.cancer.gov/ 20. Reid AE, Koziel MJ, Aiza I, Jeffers L, Reddy R, Schiff E, Lau JY, Dienstag JL,
faststats. [Last accessed on 2015 Feb 04]. Liang TJ. Hepatitis C virus genotypes and viremia and hepatocellular
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates carcinoma in the United States. Am J Gastroenterol 1999;94:1619-26.
of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 21. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular
2010;127:2893-917. carcinoma. Gastroenterology 2004;127:S62-71.
3. Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of 22. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL,
gastrointestinal cancer in Asia: an overview. Gastroenterol Hepatol Bed Beasley P, Patt YZ. Risk factors for hepatocellular carcinoma: synergism
Bench 2015;8:19-27. of alcohol with viral hepatitis and diabetes mellitus. Hepatology
4. Liver Cancer. Available from: http://www.livestrong.com. 2002;36:1206-13.
[Last accessed on 2015 Feb 04]. 23. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging
5. Amin J, Dore GJ, O’Connell DL, Bartlett M, Tracey E, Kaldor JM, of hepatitis C virus (HCV)-infected persons in the United States:
Law MG. Cancer incidence in people with hepatitis B or C infection: a a multiple cohort model of HCV prevalence and disease progression.
large community-based linkage study. J Hepatol 2006;45:197-203. Gastroenterology 2010;138:513-21, 521.e1-6.
6. Ulcickas Yood M, Quesenberry CP Jr, Guo D, Wells K, Shan J, Sanders L, 24. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK,
Skovron ML, Iloeje U, Caldwell C, Manos MM. Incidence of hepatocellular Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL,
carcinoma among individuals with hepatitis B virus infection identifi ed Dienstag JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial
using an automated data algorithm. J Viral Hepat 2008;15:28-36. Group. Incidence of hepatocellular carcinoma and associated risk
7. World Health Organization. International Agency for Research on factors in hepatitis C-related advanced liver disease. Gastroenterology
Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to 2009;136:138-48.
Humans. Hepatitis Viruses. Vol. 59. Lyon, France: International Agency 25. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, Chen CJ.
for Research on Cancer; 1994. Nomograms for risk of hepatocellular carcinoma in patients with chronic
8. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular hepatitis B virus infection. J Clin Oncol 2010;28:2437-44.
carcinoma: epidemiological characteristics and disease burden. J Viral 26. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K,
Hepat 2009;16:453-63. Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan.
9. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related Gastroenterology 2004;127:S17-26.
hepatocellular carcinoma. World J Gastroenterol 2008;14:1652-6. 27. El-Serag HB. Hepatocellular carcinoma: recent trends in the United
10. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, States. Gastroenterology 2004;127:S27-34.
Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, 28. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN.
Persico M, Fagiuoli S, Almasio PL; Italian Association of the Study of the The incidence and risk factors of hepatocellular carcinoma in patients
Liver Disease (AISF). Sustained virological response to interferon-alpha with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
is associated with improved outcome in HCV-related cirrhosis: a 29. Li P, Cao Y, Li Y, Zhou L, Liu X, Geng M. Expression of Wnt-5a and ß-catenin
retrospective study. Hepatology 2007;45:579-87. in primary hepatocellular carcinoma. Int J Clin Exp Pathol 2014;7:3190-5.
11. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, 30. Bruix J, Sherman M; Practice Guidelines Committee, American
Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Association for the Study of Liver Diseases. Management of
Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial hepatocellular carcinoma. Hepatology 2005;42:1208-36.
Group. Maintenance peginterferon therapy and other factors associated 31. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies
with hepatocellular carcinoma in patients with advanced hepatitis C. on the combined effect of hepatitis B and C virus infections in causing
Gastroenterology 2011;140:840-9. hepatocellular carcinoma. Int J Cancer 1998;75:347-54.
12. Kwon H, Lok AS. Does antiviral therapy prevent hepatocellular 32. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A,
carcinoma? Antivir Ther 2011;16:787-95. Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol
13. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, and hepatocellular carcinoma: the effect of lifetime intake and hepatitis
Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding virus infections in men and women. Am J Epidemiol 2002;155:323-31.
the natural history of nonalcoholic steatohepatitis: from cryptogenic 33. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening
cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
14. Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk 34. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnù L,
factor for hepatocellular carcinoma: mechanisms and implications. Gut Zoli M, Grazi GL, Del PP, Di N, Bernardi M; Italian Liver Cancer
2010;59:1303-7. Group. Semiannual and annual surveillance of cirrhotic patients
15. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, for hepatocellular carcinoma: effects on cancer stage and patient

4 Hepatoma Research | Volume 1 | Issue 1 | April 15, 2015